"In this current incarnation Anavex Life Sciences appears to be very generous with its management, namely the CEO, according to the company filing here, Anavex Lifesciences CEO was awarded compensation worth $2.66 million for the year 2013 and $650,000 for the year 2014, a level of compensation on par with what CEOs in the sector are paid for jobs at companies employing tens if not hundreds of employees. In any case this sounds extremely high for such a small venture or a biotech startup. As far as one can tell it appears that in 2013 and for at least part of 2014 the CEO was the only full time employee of Anavex Life Sciences, so it seems that he was extremely well compensated for the job of managing himself.
Equally at more than $2,000,000+ for the year 2014, the level of “General & Administrative Expenses” seems also incredibly high for a venture with even 5 employees, and even taking into account the fact that Anavex rents offices at a very expensive address in the famous CBS building(some ventures often like to setup shop in the most prestigious addresses and have a lot of fancy titles in the hope it will help compensate for the lack of substance). Given the fact that the company seemed to have only 1 full time employee for most of 2014, the CEO job must also come with some very enviable perks.
(On Saturday, November 7, 2015, Anavex Life Sciences presented the trial data that was advertised has revolutionary and groundbreaking in the promotion referenced at the beginning of this article, and was portrayed as the starting point of miraculous gains, I will refrain from commenting on the data at length since a number of people have already given opinions and from what I can gather it appears to have shown not statistically significant results and a flawed trial(a very small “n” called Phase2 trial(while designed like a Phase1) that was unblinded and had no placebo control arm.))
In my opinion the trial was successful in its main purpose: creating a run-up in the stock price and give some material for coordinated promotion operations.
To conclude, Anavex Life Sciences(AVXL), appears to be somewhat of a phenomenon in the world of stock promotion schemes for its longevity, sophistication and scale.
In an era where unprecedented amounts of funds are, and have been flowing into the biotechnology sector over the past 5 years, chasing any investment opportunity/asset with the slightest chance of success, it seems very unlikely that any asset holding a possible chance at a major breakthrough in the treatment of Alzheimer’s disease(an obviously very large market) would be left drifting and dormant for someone to come around and pick it up for pennies."
Market Data 
Markets 
AI
